Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction notification and does not contain comprehensive financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific increase in the notional allocation of American Depositary Shares (ADSs) for Director Dr. M. M. Slaoui due to a revaluation of the cash element within the US Retirement Savings Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: The notional allocation increase occurred on February 15, 2013.
- Director Involved: Dr. M. M. Slaoui.
- Shares Affected: 18 ADSs were added to the notional allocation.
- Price Reference: The transaction was valued at $45.62 per ADS.
- Plan Context: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK ADSs.